MGTA Stock - Magenta Therapeutics, Inc.
Unlock GoAI Insights for MGTA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $6.24M | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | 0.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-101,864,000 | $-80,902,000 | $-74,692,000 | $-78,702,000 | $-82,969,000 |
| Net Income | $-84,969,000 | $-72,022,000 | $-65,560,000 | $-69,192,000 | $-68,726,000 |
| Net Margin | -1362.8% | N/A | N/A | N/A | N/A |
| EPS | $-21.75 | $-23.05 | $-1.12 | $-1.43 | $-1.75 |
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 25th 2022 | Goldman | Downgrade | Neutral | $2 |
Earnings History & Surprises
MGTAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 1, 2024 | — | — | — | — |
Q2 2024 | May 13, 2024 | — | — | — | — |
Q4 2023 | Nov 2, 2023 | $-0.30 | $-0.27 | +10.0% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $0.19 | $0.05 | -73.7% | ✗ MISS |
Q2 2023 | Jun 5, 2023 | $0.41 | $-8.21 | -2102.8% | ✗ MISS |
Q1 2023 | Mar 8, 2023 | $-0.27 | $-7.38 | -2633.6% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $0.31 | $0.27 | -12.9% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $0.37 | $0.29 | -21.6% | ✗ MISS |
Q2 2022 | May 16, 2022 | $0.34 | $0.39 | +14.7% | ✓ BEAT |
Q1 2022 | Mar 8, 2022 | $0.32 | $0.33 | +3.1% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $0.32 | $0.30 | -6.3% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $0.35 | $0.32 | -8.6% | ✗ MISS |
Q2 2021 | May 6, 2021 | $0.40 | $0.36 | -10.0% | ✗ MISS |
Q1 2021 | Mar 3, 2021 | $0.43 | $0.38 | -11.6% | ✗ MISS |
Q4 2020 | Nov 5, 2020 | $0.45 | $0.37 | -17.8% | ✗ MISS |
Q3 2020 | Aug 6, 2020 | $0.53 | $0.48 | -9.4% | ✗ MISS |
Q2 2020 | May 7, 2020 | $0.61 | $0.51 | -16.4% | ✗ MISS |
Q1 2020 | Mar 3, 2020 | $0.58 | $0.59 | +1.7% | ✓ BEAT |
Q4 2019 | Nov 13, 2019 | $0.53 | $0.54 | +1.9% | ✓ BEAT |
Q3 2019 | Aug 8, 2019 | $0.49 | $0.48 | -2.0% | ✗ MISS |
Latest News
Frequently Asked Questions about MGTA
What is MGTA's current stock price?
What is the analyst price target for MGTA?
What sector is Magenta Therapeutics, Inc. in?
What is MGTA's market cap?
Does MGTA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MGTA for comparison